Tag: proof of concept
PharmNovo secures CTA approval in Spain
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the...
PharmNovo’s CTA submission for lead candidate PN6047
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the...